Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.30 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12362361 | 0.95 | CTSB (0.36) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL12362359 | 0.95 | CTSB (0.39) | CTSBPPP3CBCTSSCYP3A4ABCC1 | |
| SCHEMBL996322 | 0.88 | CTSB (0.39) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL8248728 | 0.88 | CTSB (0.39) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL12382940 | 0.88 | CTSB (0.34) | CTSBPPP3CBCYP3A4 | |
| SCHEMBL998163 | 0.88 | CTSB (0.39) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL12362386 | 0.88 | CTSB (0.39) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL12358243 | 0.87 | CTSB (0.40) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL11887172 | 0.85 | CTSB (0.39) | CTSBPPP3CBCTSSCYP3A4 | |
| SCHEMBL12383126 | 0.85 | CTSB (0.35) | CTSBPPP3CBCTSSCYP3A4ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-08-21 | — | — | US | disclosed |
| WO-2007014918-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | HAVCR2, HCCS, CYP7A1 | CTSB 1153/4885PPP3CB 627/4885CTSS 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.